| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | — | +188.1% |
| Cost of Revenue | $701K | — | +122.8% |
| R&D Expense | $606K | — | +51.1% |
| SG&A Expense | $1.7M | — | +239.6% |
| Operating Income | -$1.6M | — | -119.9% |
| Pre-tax Income | -$1.5M | — | -104.6% |
| Net Income | -$1.5M | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $25.9M | +614.4% | +640.0% |
| Accounts Receivable | $1.2M | +29.7% | +287.4% |
| Current Assets | $40.2M | +132.0% | +898.9% |
| Total Assets | $42.7M | +119.8% | +571.8% |
| Current Liabilities | $768K | +8.9% | -70.8% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$815K | — | +12.5% |
| Capital Expenditures | $210K | — | — |
| Investing Cash Flow | -$210K | — | — |
| Financing Cash Flow | $23.4M | — | +645.1% |
| Free Cash Flow | -$1.0M | — | -9.8% |
| -104.6% |
| EPS (Basic) | -$0.09 | — | -50.0% |
| EPS (Diluted) | -$0.09 | — | -50.0% |
| $1.8M |
| +16.7% |
| -62.0% |
| Stockholders' Equity | $40.9M | +128.5% | +2286.3% |